Status and phase
Conditions
Treatments
About
Acute falciparum malaria is associated with low plasma arginine and impaired nitric oxide (NO) production. Both are associated with poor outcome. This study will examine the safety and effect of escalating doses of arginine in falciparum malaria. It will determine whether arginine can increase NO production and have an effect on NO-dependent physiological measurements. The hypothesis is that arginine: will be safe in falciparum malaria; will return plasma arginine concentration to normal/supranormal levels; will increase systemic and exhaled NO; reduces oxidant stress; and improves a number of NO-dependent physiological measures of relevance to malaria.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Pregnancy or lactation
Mixed infection with P. falciparum and P. vivax
Warning signs of altered mental state and inability to sit unaided
Features of severe/complicated malaria
Diabetes
Systolic blood pressure (BP) < 100 mmHg
Serious underlying disease (cardiac, hepatic, kidney)
Initial iSTAT test showing any of the following values:
Known allergy to L-arginine
Concurrent therapy with any of the following medications:
Primary purpose
Allocation
Interventional model
Masking
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal